On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
ThursdayMar 19, 2020 9:31 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Commences COVID-19 Drug Delivery Program

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced the initiation of a program, in collaboration with leading laboratories in Canada and the USA, to analyze the benefits of Lexaria's DehydraTECH(TM) drug delivery platform for improving delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. Researchers around the world are currently examining several antiretroviral drugs, many of which are fat soluble, as possible candidates to combat COVID-19. When administered in oral form, fat soluble drugs are known to present considerable bioavailability challenges in effectively reaching the human bloodstream.…

Continue Reading

ThursdayMar 05, 2020 1:19 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Successful Processing of DehydraTECH(TM)-Enabled Nanoemulsion for CBD Beverages

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Wednesday announced successful processing of its first DehydraTECH(TM)-enabled liquid nanoemulsion for cannabidiol ("CBD") beverages for one of its licensed clients. Per the update, Lexaria's client expects to soon begin distribution of its line of CBD beverages in select stores across the U.S. Emulsified DehydraTECH processing is an additional service Lexaria can now provide to qualifying clients wanting to formulate best in class ready-to-drink beverages containing CBD. As referenced in a February 13 press release, Lexaria recently added this additional capability to its powder production facility.…

Continue Reading

ThursdayFeb 27, 2020 2:55 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizing DehydraTECH Technology to Power Cannadips Cannabis Products

British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently expanded on its relationship with Cannadips through a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips' cannabis products in Cannadips’ current California market and throughout the United States (http://ibn.fm/N0pdA). An article discussing the company reads, “Lexaria’s DehydraTECH drug-delivery platform is perfectly suited to improve the dipping experience through its effective, high-absorption technology. Cannadips uses multi-spectrum oils as base ingredients. The oils are rich in high-quality terpenes, which ensure the much-coveted entourage effect. DehydraTECH minimizes the throat irritation usually associated with some terpenes. . . . ‘Lexaria is building…

Continue Reading

TuesdayFeb 25, 2020 11:49 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enhances Cannabis Products’ Shelf-Life Potency, Addressing Industry Distribution Challenges

Many cannabis companies have struggled with declining investor interest amid product delivery shortfalls and adverse revenue reports The distribution obstacles have exacerbated company concerns by creating choking points for inventory, which can quickly lose potency in storage Lexaria Bioscience’s trademarked DehydraTECH powder-creating technology helps preserve cannabinoid effectiveness and extend storage potential 2 to 3 years The DehydraTECH platform also provides a key benefit in making cannabinoids, nicotine, NSAIDs and other drug products bioavailable as rapidly as inhaled products An alternative to inhaled smokes and vapes could provide health and wellness benefits to consumers by eliminating harm to users’ lungs Lexaria’s…

Continue Reading

TuesdayFeb 18, 2020 2:06 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strikes Licensing Deal with Cannadips CBD

British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently entered a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD. An article discussing the company reads, “The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO). . . . ‘This combination of superior science from Lexaria and a unique and strong branded proposition that…

Continue Reading

FridayFeb 14, 2020 11:54 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Demonstrates Applicability of Drug Delivery Platform Through Relationships with Fortune 500 Leaders

Lexaria’s DehydraTECH(TM) drug delivery platform a feasible and healthier alternative to other delivery methods The fast-acting, high absorption technology improves dipping experience and consumer satisfaction Company expects to more than double its 2019 revenue this year, will pursue a new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms and one of the few companies active in the field of cannabis to have developed formal relationships with Fortune 500 industry leaders, is experiencing strong demand from many companies requesting pre-processed DehydraTECH(TM)-enhanced bulk powders.…

Continue Reading

ThursdayFeb 13, 2020 12:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Cannabis Oral Pouch & Dip Niche through Lucrative New Partnership

Lexaria’s fast-acting, high absorption technology will improve dipping experience and consumer satisfaction Partnership will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery platform to Cannadips Cannnabis products in California and nationwide Cannadips to open one-of-a-kind cannabis oral pouch and dip research facility Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use on the latter’s market in California and nationwide according to a new definitive agreement. Currently, Cannadips Cannabis Tins are sold in California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol each, no…

Continue Reading

ThursdayFeb 13, 2020 10:09 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM)-Enabled CBD Infused Powders Available for Sale Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that its DehydraTECH(TM)-enabled CBD infused powders are now available for sale across the U.S. to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability. Consumers of both CBD/hemp and cannabis have recently become concerned about the potency and safety of the oil extract products they are purchasing. Lexaria's patented DehydraTECH(TM) technology and powder processing methodology, similar to a pasteurization technique in some ways, helps to not only preserve cannabinoid potency but also to reduce or eliminate…

Continue Reading

ThursdayFeb 06, 2020 3:09 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Providing Alternative to Inhalation via Patented Oral Drug-Delivery Technology

British Columbia-based, biodelivery technology developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is committed to the idea that better alternative methods for drug delivery exist than inhalation. A recent article discussing the company reads, “Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another. . . . The continued preference for the rapid delivery of inhaled…

Continue Reading

WednesdayJan 29, 2020 1:52 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Accelerates Delivery of CBD into Bloodstream

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://ibn.fm/Utl7A). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central-nervous-system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered